Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
AIM at Melanoma, in collaboration with its Canadian partner, the Save Your Skin Foundation, is pleased to present this informative…
09/04/2025
Hope on the Horizon: Clinical Trials & Progress in Ocular/Uveal Melanoma
AIM at Melanoma, in collaboration with its Canadian partner, the Save Your Skin Foundation, is pleased to present this informative…
08/26/2025
Back to AIM: Advocacy, Walks, and Fall Initiatives in Melanoma
For AIM at Melanoma, August is all about getting ready for a busy September and fall. While August/September is Back…
08/26/2025
Side Effect Central – Cutaneous Squamous Cell Carcinoma and Keratoacanthoma
Side Effect Central is a series of articles designed to help patients with melanoma and their caregivers understand the side…
|
08/26/2025
Newly Published Trial Data for Melanoma
Focus on TIGIT Immunotherapy What Is Immunotherapy? Many people with healthy immune systems still develop cancer. Sometimes the immune system…
|
08/26/2025
RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…
|
08/12/2025
Remembering Brandon Blackstock: A Call to Action on Melanoma Awareness
Difficult News and A Reminder of the Impact of Melanoma Today we would like to acknowledge the recent death of…
|
08/12/2025
AYA Cancer Conversation: Navigating Young Adult Cancer
We’re excited to share the latest episode of the AIM at Melanoma podcast, featuring an inspiring conversation with Abby Singh,…
|
08/11/2025
IO Biotech Announces Phase 3 Results for Cylembio® + KEYTRUDA® in Advanced Melanoma
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT) today announces topline results from the pivotal Phase…
|
|
07/25/2025
The FDA Said No — Now We Need Your Voice
Dear Friends, A recent FDA decision denied approval of a promising new treatment called RP1 for advanced melanoma—one that showed…
|
|
07/18/2025
Understanding Tumor Genetics and Melanoma: A Recap of Our Latest Webinar
In the age of precision medicine, understanding the genetics of a tumor—not just a person’s inherited DNA—is playing a critical…
|
Recent Posts
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
Jan. 21, 2026
Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026
Jan. 13, 2026